Actively Recruiting
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Led by Johnson & Johnson Enterprise Innovation Inc. · Updated on 2026-05-08
126
Participants Needed
10
Research Sites
437 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
CONDITIONS
Official Title
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC
- Have at least 1 injectable tumor
- Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1
- A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study
- Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
You will not qualify if you...
- Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed
- Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy
- Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents
- History of solid organ or hematologic stem cell transplantation
- Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome
- History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
2
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Suspended
3
UPMC Cancer Centers
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
4
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
7
Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
8
Hosp Univ Vall D Hebron
Barcelona, Spain, 08035
Actively Recruiting
9
Hosp Univ Fund Jimenez Diaz
Madrid, Spain, 28040
Actively Recruiting
10
Hosp Univ Hm Sanchinarro
Madrid, Spain, 28050
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here